In this Fierce Pharma article, our CEO Richard Pops discusses how our deep expertise in #neuroscience and advanced molecular design capabilities are fueling our path forward. Read the full article to learn more about the evolution of our company’s focus and how we are working to make a lasting difference for patients: https://lnkd.in/gtRkbcvm
Alkermes
Biotechnology Research
Alkermes is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience.
About us
At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized. Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions. Beyond our important mission of developing medicines, we believe it is our responsibility to take a holistic approach as we seek to support patients, caregivers and broader impacted communities. We remain committed to patient engagement, responsible and sustainable operations, and equitable access to quality treatment. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. See our Community Guidelines: https://www.alkermes.com/social-community-guidelines
- Website
-
https://www.alkermes.com/
External link for Alkermes
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Dublin
- Type
- Public Company
- Founded
- 1987
- Specialties
- Pharma, Pharmaceutical, Sales, Marketing, IT, CNS, Addiction, Information technology, Human Resources, Sales, District Sales, Regional Sales, Research & Development, R&D, Manufacturing, Medical Affairs, serious mental illness, biotech, addiction, narcolepsy, neuroscience, sleep disorders, and biotech
Locations
-
Primary
Get directions
Connaught House
1 Burlington Road
Dublin, IE
-
Get directions
900 Winter St
Waltham, Massachusetts 02451, US
-
Get directions
265 Olinger Circle
Wilmington, OH 45177, US
Employees at Alkermes
Updates
-
This week, #TeamAlkermes attended #SLEEP2024 to share and explore the latest scientific advancements in sleep. Along with providing updates from our #narcolepsy research program , our team enjoyed meeting with other experts in the sleep medicine community. Thanks to the American Academy of Sleep Medicine and the Sleep Research Society for hosting this valuable time to come together.
-
-
Did you know today is #WorldEnvironmentDay? Created by the United Nations in 1973, this day offers an opportunity to raise awareness of the importance of protecting and preserving our shared environment. On #TeamAlkermes, we take this responsibility seriously, and work hard to operate in an environmentally-friendly manner. To learn more about our approach, visit our website: https://bit.ly/3x57nji
-
-
Happy #PrideMonth! #TeamAlkermes stands with the LGBTQ+ community and allies, in their efforts to amplify inclusion in healthcare. To celebrate the month accordingly, we’re kicking it off with this resource from the Recovery Research Institute that shares recovery materials for members of the LGBTQ+ community living with a #substanceusedisorder: https://lnkd.in/g-_GFiS7
-
-
Did you know that narcolepsy impacts an estimated three million people worldwide? While there is currently no cure, medication and lifestyle changes may help to manage symptoms. Watch this video to learn more. #SLEEP2024
-
Test your orexin knowledge during #SLEEP2024.
This content isn’t available here
Access this content and more in the LinkedIn app
-
Tom Harvey, #TeamAlkermes' Chief Information Officer and executive sponsor of our Pride@Work ERG spoke with Pharmaceutical Executive about the importance of executive leadership in fostering a diverse workplace. Read the article: https://bit.ly/3X43Igj
-
-
Hear from Renato Chiarella, Ph.D., #TeamAlkermes’ Senior Director, Head of Formulation Development and co-lead of our MOSAIC employee resource group as he shares his thoughts on the importance of embedding diversity, inclusion and belonging (DIB) into our work as a neuroscience company. In this piece, Renato reflects on his team’s commitment to DIB as we recruit for new development and manufacturing roles. Read more: https://bit.ly/4c4zlKV
-
-
June is #MensHealthMonth, a great time to explore the facts on men’s mental health. Did you know that 90% of people diagnosed with #schizophrenia before age 30 are men? This infographic from Mental Health America spreads awareness on mental illness in men and includes statistics, the science behind mental health, famous male athletes living with a #mentalillness, and more: https://bit.ly/3Vch07V
-
-
Advocacy plays a crucial role in raising awareness and understanding of the burden caused by #narcolepsy and other sleep disorders. Events like this weekend’s #BeyondSleepy conference are vital for the sleep community, fostering impactful discussions and connections. A big thank you to Hypersomnia Foundation for bringing us together to engage in these crucial dialogues.